🇺🇸 FDA
Pipeline program

Pimavanserin 34 milligrams (MG) [Nuplazid]

2019-001722-10

Phase 2 small_molecule terminated

Quick answer

Pimavanserin 34 milligrams (MG) [Nuplazid] for Schizophrenia is a Phase 2 program (small_molecule) at ACADIA PHARMACEUTICALS INC with 1 ClinicalTrials.gov record(s).

Program details

Company
ACADIA PHARMACEUTICALS INC
Indication
Schizophrenia
Phase
Phase 2
Modality
small_molecule
Status
terminated

Clinical trials